411 Adherence to Evidence-Based Guidelines in the Treatment of HCV Genotype 2 or 3 Infection. A Real Life Experience

Hepatitis C: Understanding factors that influence the physicians' treatment decisions

“…Although insights focused on specific stages of treatment are not highly explicit in the literature, in general, decisions to initiate, adapt, discontinue treatment and/or adjust dosage are predominantly raised in the context of special population groups, side-effects, non-responsiveness and comorbidities. Dalgard et al (2011) examined physician adherence to guidelines for HCV (genotype 2 and 3) treatment in a study, including France, Germany, Italy, Spain and the UK, building on physician-reported data. They identified that adherence to duration guidelines is lower for older patients and when decisions were made by infectious disease specialists.…”